Advanced search
Publication Cover
Climacteric Volume 17, 2014 - Issue 5
Submit an article Journal homepage
607
Views
10
CrossRef citations to date
0
Altmetric
REVIEWS

Endocrine resistance in breast cancer

L. H. ZhengDepartment of Breast Cancer Center
,
Y. H. Zhao *Department of Orthopedics, The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China
,
H. L. Feng *Department of Orthopedics, The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China
&
Y. J. LiuDepartment of Breast Cancer CenterCorrespondence[email protected]
Pages 522-528 | Received 08 Sep 2013, Accepted 06 Nov 2013, Published online: 19 Dec 2013
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

Selective estrogen receptor modulators (SERMs) are synthetic molecules which bind to estrogen receptors (ER) and can modulate their transcriptional capabilities in different ways in diverse estrogen target tissues. Unfortunately, the use of resistant therapy is associated with acquired resistance. Several molecular mechanisms have been proposed to be responsible for endocrine resistance in breast cancer, including MIR-451, FGF and FGFR, ADAM12, fibronectin and other soluble stromal factors, PELP1-KDM1, HER2, NOTCH, δEF1, mTOR, AKT/mTOR, Pi3K/AKT, Pi3K/AKT/mTOR, NFκB, LMTK3, IGF1R, cyclin E2, IRF1, Tab2, and SRC-1. Further research is needed to know more about endocrine resistance.

Conflict of interest The authors report no conflict of interest. The authors alone are responsible for the content and writing of this paper.

Source of funding Nil.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related Research Data

Metastatic Progression with Resistance to Aromatase Inhibitors Is Driven by the Steroid Receptor Coactivator SRC-1
Source: American Association for Cancer Research (AACR)
New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists.
Source: Springer Science and Business Media LLC
Disease burden and treatment outcomes in second-line therapy of patients with estrogen receptor-positive (ER+) advanced breast cancer: a review of the literature.
Source: Elsevier BV
Microenvironment-Induced Non-sporadic Expression of the AXL and cKIT Receptors Are Related to Epithelial Plasticity and Drug Resistance.
Source: eScholarship, University of California
LMTK3 is implicated in endocrine resistance via multiple signaling pathways
Source: Springer Science and Business Media LLC
Association of body mass and systemic immune-inflammation indices with endocrine therapy resistance in luminal breast cancers:
Source: SAGE Publications
Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer.
Source: Springer Science and Business Media LLC
mTOR and cancer: insights into a complex relationship.
Source: Springer Science and Business Media LLC
Concerted activation of ETS protein ER81 by p160 coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu.
Source: American Society for Biochemistry & Molecular Biology (ASBMB)
Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells.
Source: Springer Science and Business Media LLC
ADAM12 induces estrogen-independence in breast cancer cells
Source: Springer Science and Business Media LLC
Discovery of estrogen receptor α target genes and response elements in breast tumor cells
Source: Springer Science and Business Media LLC
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy.
Source: Impact Journals, LLC
The steroid receptor coactivator-1 regulates twist expression and promotes breast cancer metastasis.
Source: American Association for Cancer Research (AACR)
Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks.
Source: American Society for Microbiology
Production and actions of estrogens.
Source: Massachusetts Medical Society
AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies.
Source: Springer Science and Business Media LLC
Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells
Source: American Association for Cancer Research (AACR)
Acquired Resistance to Tamoxifen Is Associated with Loss of the Type I Insulin-like Growth Factor Receptor: Implications for Breast Cancer Treatment
Source: American Association for Cancer Research (AACR)
Upstream and downstream of mTOR
Source: Cold Spring Harbor Laboratory
Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line
Source: Elsevier BV
Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance
Source: Springer Science and Business Media LLC

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.